TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31095438

Group type: EXPERIMENTAL
Intervention: Autoantibodies against Ro52, Ro60, and La in SS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autoantibodies against Ro52, Ro60, and La in ICIS patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autoantibodies against Ro52 and La in APECED patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ro60 autoantibodies in APECED patients with sicca
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Seropositivity against BPIFA1, BPIFA2/PSP, and lactoperoxidase in APECED patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum autoantibodies against BPIFA1 in APECED patients with sicca
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum autoantibodies against BPIFA2/PSP in APECED patients with sicca
Number of subjects: 0
Study: 31095609

Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia (P-Alb < 34g/L)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Normal albumin levels (P-Alb ≥ 34g/L)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Decrease in P-Alb levels
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Baseline P-Alb levels
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Adjusted odds ratios for death at 90 days
Number of subjects: 178
Study: 31095831

Group type: EXPERIMENTAL
Intervention: Algorithm for identifying inpatient overdose/oversedation events
Number of subjects: 235
Study: 31096006

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) therapy with sustained virologic response (SVR)
Number of subjects: 1601
Study: 31096041

Group type: EXPERIMENTAL
Intervention: Day case surgery (DCS)
Number of subjects: 296
Study: 31096937

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 1.5 g/kg/day, days 1-3, with mFOLFOX6 or FOLFIRI
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) at 0.2-1.5 g/kg, 3-h infusion, once daily, days 1-3, with mFOLFOX6 or FOLFIRI
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA)
Number of subjects: 36
Study: 31096944

Group type: EXPERIMENTAL
Intervention: Multifaceted community-based intervention including parent workshops on nutrition and physical activity, school-based nutrition lessons, enhanced physical education, and monthly vouchers for fruits and vegetables.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Comparison community (no intervention).
Number of subjects: 700
Study: 31096979

Group type: EXPERIMENTAL
Intervention: Dienogest (2 mg/daily)
Number of subjects: 100
Study: 31097012

Group type: EXPERIMENTAL
Intervention: Fluid challenge (FC) of 500 mL crystalloids over 10 min
Number of subjects: 143
Study: 31097024

Group type: EXPERIMENTAL
Intervention: Intermittent nivolumab for 12 weeks; 5 patients (36%) met criteria for intermittent phase with a median tumor burden decrease of 46%; all agreed to intermittent therapy.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intermittent nivolumab; acceptance rate for intermittent therapy was 100% among those eligible (5 out of 5).
Number of subjects: 14
Study: 31097027

Group type: EXPERIMENTAL
Intervention: Methacholine challenge
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Exercise challenge in ambient temperature
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Exercise challenge in cold chamber (ECC)
Number of subjects: 78
Study: 31097161

Group type: EXPERIMENTAL
Intervention: FFR >0.80 group with lesions having ≥3 HRPC
Number of subjects: 299

Group type: COMPARATOR
Intervention: FFR ≤0.80 group
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Overall analysis of lesions with ≥3 HRPC
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: FFR and number of HRPC
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Presence of ≥3 HRPC
Number of subjects: 299
Study: 31097294

Group type: EXPERIMENTAL
Intervention: Intravenous morphine (10 mg/70 kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study: 31097487

Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine introduction
Number of subjects: 116871
Study: 31097627

Group type: EXPERIMENTAL
Intervention: Olaptesed pegol (NOX-A12) with bendamustine and rituximab
Number of subjects: 28
Study: 31098625

Group type: EXPERIMENTAL
Intervention: Colostrum to transitional milk
Number of subjects: 33

Group type: COMPARATOR
Intervention: Mature milk compared to colostrum
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lactation period
Number of subjects: 33
Study: 31098682

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 26
Study: 31098986

Group type: EXPERIMENTAL
Intervention: Interpretative phenomenological analysis (IPA) method applied to semi-structured face-to-face interviews
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Personal recovery paradigm
Number of subjects: 5
Study: 31099092

Group type: EXPERIMENTAL
Intervention: Maternity waiting home
Number of subjects: 0

Group type: COMPARATOR
Intervention: No maternity waiting home (control)
Number of subjects: 0
Study: 31099252

Group type: EXPERIMENTAL
Intervention: AMD11070 (an orally administered CXCR4 entry inhibitor)
Number of subjects: 0
Study: 31099895

Group type: EXPERIMENTAL
Intervention: CYP450 activities assessed after a single oral administration of a cocktail of probe drugs
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CYP1A2 and CYP2C9 activities
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: CYP2D6 and CYP2E1 activities
Number of subjects: 73
Study: 31100122

Group type: EXPERIMENTAL
Intervention: WHIV
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-HIV-infected women
Number of subjects: 34
Study: 31100456

Group type: EXPERIMENTAL
Intervention: Remission-time equivalents (RTE) for symptom severity or treatment-related risk
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Avoidance of active symptoms
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Avoidance of corticosteroid use
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Avoidance of risks of cancer, infection or surgery
Number of subjects: 812
Study: 31100700

Group type: EXPERIMENTAL
Intervention: High-intensity training of the affected dorsiflexors for 6 weeks
Number of subjects: 20
Study: 31101048

Group type: EXPERIMENTAL
Intervention: Total hip replacement (THR) patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 30
Study: 31101095

Group type: EXPERIMENTAL
Intervention: Community garden participation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no community gardening)
Number of subjects: 160
Study: 31101367

Group type: EXPERIMENTAL
Intervention: Carotid stenosis <70%
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Carotid plaques of intermediate severity
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Female gender and systemic factors (hypercholesterolemia, lower GFR)
Number of subjects: 51
Study: 31101422

Group type: EXPERIMENTAL
Intervention: emm75 GAS doses applied by swab to the pharynx
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics treatment for all participants
Number of subjects: 0
Study: 31101489

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with R-CHP (cyclophosphamide, doxorubicin, prednisone)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin in combination with G-CHP (obinutuzumab, cyclophosphamide, doxorubicin, prednisone)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Number of subjects: 85
Study: 31101577

Group type: EXPERIMENTAL
Intervention: Folic acid (1 to 5 mg daily)
Number of subjects: 77
Study: 31101596

Group type: EXPERIMENTAL
Intervention: Skin magnifier with polarized light (SMP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Advanced dermoscope
Number of subjects: 73
Study: 31101691

Group type: EXPERIMENTAL
Intervention: Radiomic signature (SPECTRA Score) combining decrease in STL, density and computed texture analysis of the DLL at baseline and 2-month CT
Number of subjects: 491

Group type: COMPARATOR
Intervention: RECIST1.1 criteria
Number of subjects: 491
Study: 31102044

Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD) protocol including full-mouth scaling and root planing within 24 hours, application of chlorhexidine digluconate (CHX) gel in pockets and tongue plus CHX rinses for 14 days
Number of subjects: 54
Study: 31102113

Group type: EXPERIMENTAL
Intervention: AI-guided pulmonary vein isolation (OAI group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional contact force-guided pulmonary vein isolation (CON group)
Number of subjects: 70
Study: 31102143

Group type: EXPERIMENTAL
Intervention: Immuno-Oncology (IO) treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard parametric models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cure, parametric mixture and response-based landmark models
Number of subjects: 0
Study: 31102144

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 155 U administered every 12 weeks
Number of subjects: 716

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA treatment
Number of subjects: 716
Study: 31103027

Group type: EXPERIMENTAL
Intervention: Airflow obstruction group
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Subjects with exacerbation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Subjects with airflow obstruction
Number of subjects: 201

Group type: COMPARATOR
Intervention: Overall health status decline
Number of subjects: 201
Study: 31103379

Group type: EXPERIMENTAL
Intervention: qSOFA-based triage procedure
Number of subjects: 678

Group type: COMPARATOR
Intervention: Standard triage procedures only (baseline)
Number of subjects: 678
Study: 31103489

Group type: EXPERIMENTAL
Intervention: Single-modal training (SMT, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Multi-modal training (MMT, n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both SMT and MMT
Number of subjects: 20
Study: 31104307

Group type: EXPERIMENTAL
Intervention: Solid organ transplant recipients (sOTRs)
Number of subjects: 2758
Study: 31104495

Group type: EXPERIMENTAL
Intervention: Proteomic biomarkers associated with incident HF (discovery phase)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Proteomic biomarkers associated with incident HF (replication phase)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Mechanistic pathways underlying incident HF
Number of subjects: 286
Study: 31104505

Group type: EXPERIMENTAL
Intervention: Cilostazol (experimental migraine trigger)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sumatriptan (6 mg s.c.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No migraine-specific rescue medication
Number of subjects: 28
Study: 31104544

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) for boys at 10th and 50th percentiles of HDI
Number of subjects: 6548

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) for girls at 10th and 50th percentiles of HDI
Number of subjects: 6548

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) for girls at 90th percentile of HDI
Number of subjects: 6548

Group type: EXPERIMENTAL
Intervention: Sedentary time for boys at 10th percentile of HDI
Number of subjects: 6548

Group type: EXPERIMENTAL
Intervention: Sedentary time for girls
Number of subjects: 6548
Study: 31104545

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT)
Number of subjects: 20
Study: 31104619

Group type: EXPERIMENTAL
Intervention: Intensive CPAP adherence program
Number of subjects: 90
Study: 31104821

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting BVS
Number of subjects: 1002
Study: 31104850

Group type: EXPERIMENTAL
Intervention: Cow's milk-fat percentage intake
Number of subjects: 2890

Group type: EXPERIMENTAL
Intervention: Volume of cow's milk consumed
Number of subjects: 2890
Study: 31106141

Group type: EXPERIMENTAL
Intervention: Multi-Parametric Quantitative Magnetic Resonance Imaging
Number of subjects: 0
Study: 31106576

Group type: EXPERIMENTAL
Intervention: Young-onset dementia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Late-onset dementia
Number of subjects: 0
Study: 31106841

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 balloon-expandable transcatheter heart valve (THV)
Number of subjects: 276
Study: 31106898

Group type: EXPERIMENTAL
Intervention: Hydroxyurea, single oral dose of 20 mg/kg, followed by PK-guided dosing
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hydroxyurea, PK-guided dosing
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional weight-based dosing
Number of subjects: 50
Study: 31107260

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) system for propofol administration with BIS target between 40 and 50
Number of subjects: 163
Study: 31107300

Group type: EXPERIMENTAL
Intervention: Nucleoside reverse transcriptase inhibitors
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Non-nucleoside reverse transcriptase inhibitors
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Protease inhibitors
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Integrase inhibitors (yes or no)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (CSVD-free PLHIVs)
Number of subjects: 154
Study: 31107351

Group type: EXPERIMENTAL
Intervention: LUS-sCPIS
Number of subjects: 51

Group type: COMPARATOR
Intervention: sCPIS
Number of subjects: 51
Study: 31107869

Group type: EXPERIMENTAL
Intervention: Triple-drug therapy (IVM + DEC + ALB)
Number of subjects: 56
Study: 31107956

Group type: EXPERIMENTAL
Intervention: Azithromycin treatment
Number of subjects: 0
Study: 31108015

Group type: EXPERIMENTAL
Intervention: Ruzasvir 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks
Number of subjects: 282
Study: 31108163

Group type: EXPERIMENTAL
Intervention: Clinician-administered KSADS-COMP
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Youth self-administered KSADS-COMP
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Parent self-administered KSADS-COMP
Number of subjects: 669
Study: 31108264

Group type: EXPERIMENTAL
Intervention: Quitters (participants who had not used for at least 30 days at follow-up)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Symptomatic participants (newly or persistently symptomatic)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Chippers (participants with few symptoms)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Converted Chippers (participants with improved symptom counts)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Quitters
Number of subjects: 115
Study: 31108325

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN)
Number of subjects: 113
Study: 31108510

Group type: EXPERIMENTAL
Intervention: ITF-rich vegetables (15 g ITF/d)
Number of subjects: 26
Study: 31109199

Group type: EXPERIMENTAL
Intervention: High-frequency dTMS (20 Hz)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham dTMS
Number of subjects: 99
Study: 31109986

Group type: EXPERIMENTAL
Intervention: Patients with central sleep apnoea
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patients with obstructive sleep apnoea
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patients without SDB
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Age ≥70 years
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Central sleep apnoea
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Patients with delirium
Number of subjects: 141
Study: 31110096

Group type: EXPERIMENTAL
Intervention: CD19.CAR T cells (autologous T-lymphocytes transduced by RV-SFG.CD19.CD28.4-1BB zeta retroviral vector)
Number of subjects: 0
Study: 31110479

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MCT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (non-exercising group)
Number of subjects: 36
Study: 31110648

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 400 mg daily at bedtime from 28 weeks until delivery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no treatment other than normal tonics)
Number of subjects: 70
Study: 31111072

Group type: EXPERIMENTAL
Intervention: Serum CC16 levels on POD1
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pretransplant serum CC16 levels
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Area under the receiver operating characteristic curves for POD1 serum CC16 levels
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation and intensive care unit stay
Number of subjects: 73
Study: 31111255

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue scale
Number of subjects: 12
Study: 31111762

Group type: EXPERIMENTAL
Intervention: MDS patients
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: MDS/MPN patients
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: ICUS cases
Number of subjects: 2500
Study: 31111867

Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in Japan
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in China
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in the United Kingdom
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Salt intake 1 g/d higher in the United States
Number of subjects: 4680
Study: 31112005

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg and 10 mg
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Tofacitinib treatment
Number of subjects: 783
Study: 31112060

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 31112389

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 0
Study: 31112476

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy followed by N-AVD (doxorubicin, vinblastine, and dacarbazine)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy followed by N-AVD
Number of subjects: 51
Study: 31112777

Group type: EXPERIMENTAL
Intervention: Glasses prescribed and provided to students
Number of subjects: 197
Study: 31113375

Group type: EXPERIMENTAL
Intervention: Healthcare workers (HCWs)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Inpatients
Number of subjects: 251

Group type: COMPARATOR
Intervention: Physicians (HCWs)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Demographic factors in inpatients
Number of subjects: 251
Study: 31113456

Group type: EXPERIMENTAL
Intervention: CARDIOROOT vascular graft
Number of subjects: 52
Study: 31113467

Group type: EXPERIMENTAL
Intervention: Serum Cyr61 concentration in active RA patients
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Serum Cyr61 concentration in RA patients in remission/low disease activity
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Serum Cyr61 concentration at baseline and 12 weeks after treatment in ACR responders
Number of subjects: 177

Group type: COMPARATOR
Intervention: Serum Cyr61 concentration at baseline and 12 weeks after treatment in non-responders
Number of subjects: 177
Study: 31113766

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 6463

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: TAVR and SAVR (competing risk analysis)
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Deep sternal wound infection or vascular access-site infection
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Type of procedure (TAVR vs SAVR)
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 6463

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 6463
Study: 31113777

Group type: EXPERIMENTAL
Intervention: Daratumumab plus carfilzomib and dexamethasone (D-Kd)
Number of subjects: 85
Study: 31113837

Group type: EXPERIMENTAL
Intervention: Intravenous CPX-POM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral CPX-O
Number of subjects: 0
Study: 31114182

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31114211

Group type: EXPERIMENTAL
Intervention: Suction Above Cuff Endotracheal Tube (SACETT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Endotracheal Tube (control)
Number of subjects: 0
Study: 31114268

Group type: EXPERIMENTAL
Intervention: Grazoprevir/elbasvir in combination with peginterferon alfa plus ribavirin
Number of subjects: 0
Study: 31114301

Group type: EXPERIMENTAL
Intervention: Single-shot paravertebral block
Number of subjects: 0

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 0
Study: 31114846

Group type: EXPERIMENTAL
Intervention: Emactuzumab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emactuzumab in combination with paclitaxel (80 mg/m2 weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emactuzumab (1000 mg every 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emactuzumab (monotherapy and combination)
Number of subjects: 0
Study: 31115158

Group type: EXPERIMENTAL
Intervention: Translated EARP questionnaire (Australian version)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Translated EARP questionnaire (Korean version)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Translated EARP questionnaire (Chinese version)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Overall assessment of patients diagnosed with PsA
Number of subjects: 250
Study: 31115278

Group type: COMPARATOR
Intervention: ADHD probands
Number of subjects: 150

Group type: COMPARATOR
Intervention: Unaffected siblings
Number of subjects: 150
Study: 31115343

Group type: EXPERIMENTAL
Intervention: Yoga intervention (60-min group-based yoga sessions, 3 times a week for 12 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (maintaining current physical activity levels)
Number of subjects: 25
Study: 31115346

Group type: EXPERIMENTAL
Intervention: YMHP intervention (clinic-based delivery)
Number of subjects: 270

Group type: COMPARATOR
Intervention: YMHP intervention (remote delivery)
Number of subjects: 270
Study: 31115904

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0